Akreos posterior chamber intraocular lens
Bausch + Lomb, Inc. · Decision date Sep 3, 2026
What did the FDA decide?
The FDA record P060022/S038 is a 30-day notice for the Akreos posterior chamber intraocular lens (product code HQL, Ophthalmic), submitted by Bausch & Lomb, Inc., with a decision dated 2026-09-03. The supplement reason is listed as a process change involving a manufacturer, sterilizer, packager or supplier. The stated scope, in the record's own words, is "the elimination of certain redundant post-coating incoming inspections for coated lens shuttles."
That statement does not specify which shuttles, how many inspections are removed, or what replacement controls, if any, apply. The source describes a manufacturing-process adjustment; it does not establish safety or clinical effectiveness, and it is not a new approval of the whole lens system. The S038 suffix ties the notice to PMA P060022, but the supplied fields give no further detail on the original approval's scope.
FDA approval order statement
the elimination of certain redundant post-coating incoming inspections for coated lens shuttles
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 3, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P060022/S038
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- Decision code
- OK30
- Decision date
- Sep 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P060022. Subsequent supplements may change the device or its indications.
FDA decision timeline
P060022 · Original PMA
AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS,MODEL ADAPT
P060022/S038 received
Application receipt date recorded by FDA.
P060022/S038 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P060022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA approval | Sep 5, 2008 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 50 Technology Dr., Irvine, CA, 92618
Sources and methodology
- Original FDA record: P060022/S038
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



